Correlation between peripheral blood LMP2, RVD1 levels and cognitive impairment in acute ischemic stroke patients

Abstract:Objective To explore the correlation between peripheral low molecular mass peptide 2(LMP2), resolvin D1(RVD1), and cognitive impairment(CI) in acute ischemic stroke(AIS) patients. Methods From January 2021 to July 2024, 216 AIS patients and 65 healthy controls were enrolled. Followed for 6 months, AIS patients were divided into CI(n=72) and non-CI(n=144) subgroups. LMP2 and RVD1 levels were measured by ELISA. Pearson correlation analyzed their relationships with MMSE and MoCA scores. Multivariate Logistic regression identified CI risk factors, and ROC curves evaluated predictive value. Results AIS patients had higher LMP2 and lower RVD1 than controls(t/P=13.957/<0.001, 28.146/<0.001). LMP2 negatively correlated with MMSE/MoCA(r/P=-0.718/<0.001,-0.704/<0.001), while RVD1 showed positive correlations(r/P=0.707/<0.001, 0.726/<0.001). CI subgroup had higher LMP2 and lower RVD1(t/P=10.361/<0.001,-9.762/<0.001). Age, NIHSS score, infarct volume, and high LMP2 were independent risk factors for CI [OR=1.072(1.007-1.142), 1.500(1.271-1.771), 1.580(1.286-1.941), 1.006(1.003-1.008)], while high RVD1 was protective [OR=0.738(0.648-0.840)]. The AUCs for LMP2, RVD1, and their combination were 0.792, 0.804, and 0.895, with the combination being superior(Z/P=3.920/<0.001, 3.764/<0.001).Conclusion Elevated LMP2 and reduced RVD1 are linked to CI in AIS. Combined measurement enhances predictive efficacy.